OncoMatch/Clinical Trials/NCT05361720
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Is NCT05361720 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Ipilimumab and Nivolumab for advanced clear cell renal cell carcinoma.
Treatment: Cabozantinib · Ipilimumab · Nivolumab — This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to other places in the body (advanced or metastatic). The current Food and Drug Administration (FDA)-approved regimens for advanced kidney cancer fall into two categories. One treatment combination includes two immunotherapy drugs (nivolumab plus ipilimumab), which are delivered by separate intravenous infusions into a vein. The other combination is one immunotherapy drug (nivolumab infusion) plus an oral pill taken by mouth (cabozantinib). Nivolumab and ipilimumab are "immunotherapies" which release the brakes of the immune system, thus allowing the patient's own immune system to better kill cancer cells. Cabozantinib is a "targeted therapy" specifically designed to block certain biological mechanisms needed for growth of cancer cells. In kidney cancer, cabozantinib blocks a tumor's blood supply. The genetic (DNA) makeup of the tumor may affect how well it responds to therapy. Testing the makeup (genes) of the tumor, may help match a treatment (from one of the above two treatment options) to the specific cancer and increase the chance that the disease will respond to treatment. The purpose of this study is to learn if genetic testing of tumor tissue may help doctors select the optimal treatment regimen to which advanced kidney cancer is more likely to respond.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Disease stage
Required: Stage III, IV
Prior therapy
Lab requirements
Kidney function
calculated creatinine clearance >= 30 mL/min per Cockcroft and Gault formula
Liver function
Total bilirubin <= 1.5 x ULN (except Gilbert's syndrome); ALT and AST <= 3 x ULN
Adequate renal function defined as calculated creatinine clearance >= 30 mL/min per the Cockcroft and Gault formula; Adequate liver function defined by: Total bilirubin <= 1.5 x ULN except for unconjugated hyperbilirubinemia of Gilbert's syndrome; ALT and AST <= 3 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope National Medical Center · Duarte, California
- Chao Family Comprehensive Cancer Center · Orange, California
- University Hospitals Seidman Cancer Center · Cleveland, Ohio
- Cleveland Clinic · Cleveland, Ohio
- Vanderbilt University/Ingram Cancer Center · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify